6 patients (7%) in MS group and 12 (26,6%) in the CS group (p-value = 0 .0036) received a GnRH agonist trigger (0,3 mg of triptorelin) to prevent OHSS. Here, GNRH1 is linked to ovarian hyperstimulation syndrome.